A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer

Abstract

Mitoxantrone (Novantrone®; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer. It appears to have less toxicity than doxorubicin. Results of this phase II–III randomized cross-over trial to determine the relative efficacy and toxicity of mitoxantrone in comparison to doxorubicin, are presented. Patients with… (More)
DOI: 10.1007/BF00174163